Audentes Therapeutics (BOLD) IPO Prices at $15, Middle of Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Audentes Therapeutics (BOLD) IPO Opens Up 27%
July 20, 2016 10:36 AM EDTToday's IPO for Audentes Therapeutics (NASDAQ: BOLD) opened for trading at $19 after pricing its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share, the middle of the expected $14.00-$16.00 range.
BofA Merrill Lynch, Cowen and Company and Piper Jaffray are acting as joint... More
